Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03854474
Title Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

transitional cell carcinoma

Therapies

Pembrolizumab + Tazemetostat

Age Groups: adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST